<DOC>
	<DOCNO>NCT02053974</DOCNO>
	<brief_summary>This study seek investigate whether spironolactone protects heart anthracycline-induced cardiotoxicity .</brief_summary>
	<brief_title>Spironolactone Against Anthracycline-induced Cardiomyopathy</brief_title>
	<detailed_description>Anthracyclines cornerstone treatment numerous hematological solid cancer . The common side effect anthracycline cardiotoxicity may limit use increase rate mortality morbidity . Cardiotoxicity cumulative , dose dependent , irreversible . Improvements protective mechanism cardiotoxicity anthracycline important prevent discontinuance chemotherapeutics . Spironolactone aldosterone antagonist block last step rennin angiotensin aldosterone system ( RAAS ) . The RAAS one effective system remodel myocardium post-myocardial damage . According RALES study , patient severe heart failure , 25 mg spironolactone per day addition standard therapy positive effect , particularly cardiac fibrosis remodeling , substantially reduce risk morbidity death . In EPHESUS study , show , myocardial damage due infarction , administration aldosterone antagonists positive effect remodel process , leave ventricular ejection fraction primer end-points . In present study , test hypothesis RAAS blockage spironolactone may reduce cardiotoxicity anthracycline group chemotherapeutics .</detailed_description>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Cardiotoxicity</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>LVEF &gt; 50 % first diagnose breast cancer female sex Prior breast cancer and/or prior anthracycline exposure history LVEF &lt; 50 % Use angiotensin convert enzyme inhibitor , angiotensin receptor blocker beta blocker Creatinin value &gt; 2 mg/dl Presence chronic kidney failure Potassium value &gt; 5.3 mg/dl Presence adrenal gland disease , Presence severe liver failure Comorbidities coronary heart disease , hypertension , atrial fibrillation , valvular heart disease . Male patient exclude homogenization study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Anthracycline</keyword>
	<keyword>spironolactone</keyword>
	<keyword>cardiotoxicity</keyword>
</DOC>